IL286484A - Reagents for treatment of hepatitis b virus (hbv) infection and use thereof - Google Patents

Reagents for treatment of hepatitis b virus (hbv) infection and use thereof

Info

Publication number
IL286484A
IL286484A IL286484A IL28648421A IL286484A IL 286484 A IL286484 A IL 286484A IL 286484 A IL286484 A IL 286484A IL 28648421 A IL28648421 A IL 28648421A IL 286484 A IL286484 A IL 286484A
Authority
IL
Israel
Prior art keywords
hbv
hepatitis
virus
reagents
infection
Prior art date
Application number
IL286484A
Other languages
Hebrew (he)
Other versions
IL286484B (en
Inventor
Mao Tin
KAO Shih-Chu
Suhy David
Graham Michael
Original Assignee
Benitec Ip Holdings Inc
Mao Tin
Shih Chu Kao
Suhy David
Graham Michael
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015901617A external-priority patent/AU2015901617A0/en
Priority claimed from PCT/AU2016/050340 external-priority patent/WO2016176745A1/en
Application filed by Benitec Ip Holdings Inc, Mao Tin, Shih Chu Kao, Suhy David, Graham Michael filed Critical Benitec Ip Holdings Inc
Publication of IL286484A publication Critical patent/IL286484A/en
Publication of IL286484B publication Critical patent/IL286484B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/50Physical structure
    • C12N2310/51Physical structure in polymeric form, e.g. multimers, concatemers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/50Physical structure
    • C12N2310/53Physical structure partially self-complementary or closed
    • C12N2310/531Stem-loop; Hairpin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/10Applications; Uses in screening processes
    • C12N2320/11Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
IL286484A 2015-05-06 2021-09-19 Reagents for treatment of hepatitis b virus (hbv) infection and use thereof IL286484B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015901617A AU2015901617A0 (en) 2015-05-06 Reagents for treatment of hepatitis B virus (HBV) infection and use thereof
US201662319971P 2016-04-08 2016-04-08
PCT/AU2016/050340 WO2016176745A1 (en) 2015-05-06 2016-05-06 Reagents for treatment of hepatitis b virus (hbv) infection and use thereof

Publications (2)

Publication Number Publication Date
IL286484A true IL286484A (en) 2021-10-31
IL286484B IL286484B (en) 2022-06-01

Family

ID=78411556

Family Applications (1)

Application Number Title Priority Date Filing Date
IL286484A IL286484B (en) 2015-05-06 2021-09-19 Reagents for treatment of hepatitis b virus (hbv) infection and use thereof

Country Status (1)

Country Link
IL (1) IL286484B (en)

Also Published As

Publication number Publication date
IL286484B (en) 2022-06-01

Similar Documents

Publication Publication Date Title
IL257384A (en) Rnai-containing compositions and use of same for treating hepatitis b virus infection
IL245436A0 (en) Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
IL246449A0 (en) Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
IL244431A0 (en) Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection
IL255366A0 (en) Reagents for treatment of hepatitis b virus (hbv) infection and use thereof
SG11201703638XA (en) Hepatitis b virus (hbv) irna compositions and methods of use thereof
ZA201507840B (en) 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
IL275427A (en) Hepatitis b virus (hbv) vaccines and uses thereof
IL249660A0 (en) Methods for the treatment of hepatitis b and hepatitis d virus infections
HUE044606T2 (en) Treatment of hepatitis delta virus infection
DK3370723T3 (en) TREATMENT OF HEPATITIS DELTA VIRUS INFECTION
EP3226973A4 (en) Treatment of hepatitis delta virus infection
IL272094A (en) Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
IL271491B1 (en) Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
IL286484B (en) Reagents for treatment of hepatitis b virus (hbv) infection and use thereof
EP3452595A4 (en) REAGENTS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION AND USE THEREOF
AU2015901617A0 (en) Reagents for treatment of hepatitis B virus (HBV) infection and use thereof
HK40005312A (en) Reagents for treatment of hepatitis b virus (hbv) infection and use thereof
ZA201604784B (en) Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection